Moreover, LINC01559 has been shown to function as a competing endogenous RNA (ceRNA) of miR-1343-3p to accelerate triple-negative breast cancer progression, and similarly as a ceRNA to promote the progression of colorectal cancer and pancreatic cancer [38, 43, 44]. Here, LINC01559 is linked to pancreatic neoplasm.